Arcus Biosciences, Inc. (NYSE:RCUS) announced that it has entered into a purchase agreement with returning investor Gilead Sciences, Inc. (NasdaqGS:GILD) for private placement of 5,650,000 shares at an issue price of $39 per share for gross proceeds of $220,350,000 on January 31, 2021. Post the closing, the investor's stake in the company will increase from approximately 13% to 19.5%. The transaction is subject to customary closing conditions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.19 USD | +1.25% | -4.76% | -15.24% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.24% | 1.45B | |
+35.14% | 51.07B | |
-7.43% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+11.63% | 26.35B | |
-17.77% | 19.46B | |
+40.52% | 13.58B | |
+30.70% | 12.46B | |
-3.41% | 11.75B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Arcus Biosciences, Inc. announced that it expects to receive $220.35 million in funding from Gilead Sciences, Inc.